US EditionExperimental Lilly drug cuts genetic heart disease risk factor by 94% in trial
- Eli Lilly's experimental drug, Lepodisiran, reduced lipoprotein levels by an average of 93.9% compared to placebo in a midstage trial, involving 72 patients receiving the highest dose of 400 mg, with no serious adverse events reported during the trial.
- Dr. Steven Nissen presented results at the American College of Cardiology meeting, stating, "What we have is a drug that can lower lipoprotein with very infrequent administration."
- Lilly is conducting a second Phase 3 trial to determine if lowering lipoprotein reduces cardiovascular risks, with patient enrollment expected to be completed this year.
- Eli Lilly's drug is one of several treatments being developed for high lipoprotein, which is a risk factor affecting 1.4 billion people globally.
27 Articles
27 Articles
Morgan County Citizen
New Drug May Cut Sudden Heart Risk by 94%
Key Takeaways
New drug shows promise for treating heart disease
The NewsA new drug developed by pharmaceutical giant Eli Lilly showed promise for treating heart disease. People with high levels of lipoprotein(a) in their blood are at higher risk of cardiovascular disease, but unlike other risk factors such as cholesterol there is no existing treatment to lower it. An early-stage trial found that two tablets of an experimental drug developed by Eli Lilly taken six months apart reduced blood levels of lipoprot…
Experimental Lilly drug cuts genetic heart disease risk factor by 94% in trial
The highest dose of an experimental drug developed by Eli Lilly significantly reduced levels of a genetically inherited risk factor for heart disease in a midstage trial, according to data presented at a major medical meeting on Sunday.
Coverage Details
Bias Distribution
- 45% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
